Rindopepimut for Recurrent Glioblastoma

Clinical Pearls

David Reardon, MD, clinical director, Center for Neuro-Oncology, Dana-Farber Cancer Institute, president, Society for Neuro-Oncology, describes the mechanism of action of rindopepimut for recurrent glioblastoma.

• Rindopepimut (CDX-110) is a synthetic peptide vaccine designed to target the mutant epidermal growth factor receptor variant III.
• This mutation drives tumor growth and is present in approximately 30% of glioblastoma tumors.
• Rindopepimut sensitizes the immune system against this mutant receptor on glioblastoma tumor cells.

<<<

View more from the 2014 SNO meeting